Inflammatory mediators in nasal secretions

"Inflammatory mediators in nasal secretions" refers to a collective group of biologically active molecules, including cytokines (such as IL-4, IL-6, IL-8, IL-1), chemokines, enzymes (e.g., tryptase), heat shock proteins (e.g., HSP70), neuropeptides (e.g., substance P), and acute-phase proteins (e.g., ECP, CC16) that regulate and reflect immune and inflammatory responses in the nasal mucosa[1][2][3][4][5][6]. These mediators are increased in conditions such as chronic rhinosinusitis with or without polyps, allergic rhinitis, asthma, and infections, where they serve as biomarkers for inflammation severity, disease progression, and, in some cases, predictors of therapeutic response or airway remodeling[1][2][3][5][6]. While drugs target the effects of individual mediators (e.g., corticosteroids block multiple cytokines, biologics target specific interleukins, antihistamines block histamine), "inflammatory mediators in nasal secretions" as a whole is not a drug target but a diagnostic or pathophysiological category[1][4][6]. This entity is best understood as a panel of molecular mediators rather than a unique therapeutic target; use of this phrase as a "target" is imprecise or incorrect for molecular drug discovery or receptor profiling purposes.

Other names

Inflammatory molecules in nasal secretionsNasal inflammatory markersNasal cytokines/chemokines/proteins

Inhibition or neutralization of pro-inflammatory mediators (e.g., cytokine inhibition, receptor antagonism, blocking histamine release); Immune modulation